BioLine Rx (XTAE:BLRX) FCF Margin % : 103.60% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioLine Rx's Free Cash Flow for the three months ended in Dec. 2023 was ₪18.42 Mil. BioLine Rx's Revenue for the three months ended in Dec. 2023 was ₪17.78 Mil. Therefore, BioLine Rx's FCF Margin % for the quarter that ended in Dec. 2023 was 103.60%.

As of today, BioLine Rx's current FCF Yield % is -43.95%.

The historical rank and industry rank for BioLine Rx's FCF Margin % or its related term are showing as below:

XTAE:BLRX' s FCF Margin % Range Over the Past 10 Years
Min: -477.2 Med: -477.18 Max: -477.18
Current: -477.2

During the past 13 years, the highest FCF Margin % of BioLine Rx was -477.18%. The lowest was -477.20%. And the median was -477.18%.

XTAE:BLRX's FCF Margin % is ranked worse than
66.22% of 1048 companies
in the Biotechnology industry
Industry Median: -144.01 vs XTAE:BLRX: -477.20

BioLine Rx FCF Margin % Historical Data

The historical data trend for BioLine Rx's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx FCF Margin % Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-477.19

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	103.60

Competitive Comparison of BioLine Rx's FCF Margin %

For the Biotechnology subindustry, BioLine Rx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's FCF Margin % falls into.

BioLine Rx FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioLine Rx's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-84.858	/	17.783
	=	-477.19 %

BioLine Rx's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	18.424	/	17.783
	=	103.60 %

BioLine Rx FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.